Physician profile
Christopher L Starks
NPI 1588827968
$2,905.61
in general payments reported to CMS, 2019-2025
34 companies · $587 in 2025
The $587 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $606 · 2020: $110 · 2021: $518 · 2022: $410 · 2023: $357 · 2024: $318 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,262.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $358.62 | 2019-2023 | Xtandi |
| Coloplast Corp | $296.40 | 2019-2025 | Speedicath |
| Endo USA, INC. | $249.78 | 2024-2025 | Xiaflex, Aveed |
| Janssen Biotech, INC. | $221.60 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $221.53 | 2019-2024 | Xiaflex, Aveed |
| Procept Biorobotics Corporation | $218.16 | 2025 | |
| Myovant Sciences INC. | $118.16 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.31 | 2025 | Xifaxan |
| Olympus America INC. | $103.69 | 2022-2025 | Bovie, Cysto-Nephro Videoscope, Itind System |
| Urovant Sciences INC | $83.38 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $80.05 | 2023-2024 | Gemtesa |
| Pfizer INC. | $72.59 | 2019-2025 | |
| Hollister Incorporated | $67.53 | 2022-2023 | Infyna Chic, Vapro, Onli |
| Tactile Systems Technology INC | $56.18 | 2022 | |
| Convatec INC. | $53.90 | 2022-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $51.90 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.65 | 2019-2021 | |
| Blue Earth Diagnostics | $47.15 | 2019-2022 | |
| Dendreon Pharmaceuticals LLC | $46.54 | 2019 | |
| Halozyme INC | $42.17 | 2023 | |
| Ambu INC. | $36.73 | 2022-2024 | |
| Ferring Pharmaceuticals INC. | $35.75 | 2019-2024 | Adstiladrin |
| Teleflex LLC | $35.33 | 2021-2023 | Urolift |
| Boston Scientific Corporation | $33.87 | 2019-2020 | |
| Genentech USA, INC. | $31.75 | 2024 | Rozlytrek, Avastin, Tecentriq |
| Progenics Pharmaceuticals, INC. | $28.67 | 2023 | Pylarify |
| Novo Nordisk INC | $24.44 | 2021 | |
| Amgen INC. | $22.29 | 2020 | |
| Spectrum Pharmaceuticals INC. | $21.91 | 2024 | Rolvedon |
| Urogen Pharma, INC. | $19.65 | 2023 | Jelmyto |
| Tolmar, INC. | $18.10 | 2024 | |
| Aytu Biopharma, INC. | $17.62 | 2019 | |
| Merck Sharp & Dohme LLC | $15.35 | 2022 | |
| Axonics, INC. | $13.86 | 2024 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Starks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.